David Traylor is Senior Managing Director at Golden Eagle Partners, a firm he founded in 2012 to advise life science companies. After advising on various transactions in the life science, he took an interest in the cannabis sector and joined Surna, Inc. (OTC:SRNA) as Chief Business Officer in 2014. After close to a year stint at Surna, David re-founded Golden Eagle Partners to provide his knowledge to companies across the cannabis sector.
Before Golden Eagle Partners, David led the Life Science group at Headwaters MB, a leading boutique investment bank. Before Headwaters, David served as a Senior Vice President at Caris & Company where he was focused on biopharmaceuticals. He also previously worked with Wedbush Pacific Growth. During his banking tenures he has advised private and public biotechnology and medical device companies in various transactions including IPOs, public offerings, private offerings, mergers and acquisitions totaling close to $500 million in value.
Before investment banking, David spent fifteen years in diverse operational roles in biotechnology companies, from research and development to business development and most other functional areas. David began his career in biotechnology, with a position in bioprocess manufacturing at Synergen, and then moved into R&D and process development positions at Somatogen, a company pursuing a recombinant blood substitute. After Somatogen, he led the management of programs and development initiatives at Affymetrix, the leading innovator in microarray technology. David began his business development career at Deltagen then moved over the lead the U.S. operations for atugen AG, a Berlin-based functional genomics company. At Bioseek, David led the business development efforts for one of the first systems biology companies. Having played professional lacrosse, David is also a member athlete of Athletes For Care.